ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
얼리다 시장의 규모는 최근 현저하게 확대되고 있습니다. 2024년의 27억 6,000만 달러에서 2025년에는 30억 2,000만 달러로, CAGR 9.6%로 성장할 전망입니다. 지금까지의 성장은 호르몬 저항성 전립선암의 발생률 증가, 안드로겐 차단 요법의 사용 확대, 종양학 조사에 대한 투자 증가, 고도의 암 치료에의 접근 확대, 의사에 의한 경구 전립선암 치료제의 선호도 향상에 기인하는 것으로 예측됩니다.
얼리다 시장의 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 43억 1,000만 달러에 달하고, CAGR은 9.3%를 나타낼 전망입니다. 예측 기간에 있어서의 성장 요인으로서는 저침습 암 치료에 수요 증가, 차세대 항안드로겐의 채용 확대, 종양학 분야에 있어서의 의료 지출 증가, 정밀의료 프로그램의 이용 확대, 조기 치료에 수반하는 생존율 향상의 인지도 향상 등을 들 수 있습니다. 예측기간 동안 예상되는 주요 동향으로는 임상시험 설계에 있어서의 기술적 진보, 안드로겐 수용체를 표적으로 하는 작용기전의 혁신, 암 관리를 위한 디지털 헬스툴의 개발, 방사성 리간드 요법 및 병용 요법에 있어서의 지속적인 연구 개발, 인공지능(AI) 기반의 암 진단 기술의 진전을 들 수 있습니다.
전립선암의 유병률 상승은 향후 얼리다 시장의 성장을 가속할 것으로 예측됩니다. 전립선암은 남성 생식기계의 일부인 전립선에서 발생하는 악성 종양을 말합니다. 전립선암의 유병률 상승은 평균 수명의 연장에 기인하고 있으며, 고령화는 본 질환의 발병 리스크를 현저하게 높입니다. 얼리다는 안드로겐 수용체를 저해함으로써 전립선암의 치료를 지원하고 남성호르몬이 암세포의 증식과 전이를 촉진하는 것을 막습니다. 예를 들어, 호주 정부가 2025년 11월에 발표한 데이터에 따르면 약 2만 8,868건의 신규 전립선암 증례가 보고되었으며 이는 남성의 암 신규 진단 전체의 약 30%를 차지하고 3,975명이 사망한 것으로 추정되었습니다. 따라서 전립선암의 유병률 상승이 얼리다 시장의 성장을 견인하고 있습니다.
첨단 안드로겐 수용체 억제제의 채용 확대는 향후 얼리다 시장의 성장을 가속할 것으로 예측됩니다. 선진적인 안드로겐 수용체 억제제란 안드로겐 수용체 신호전달을 보다 효과적으로 차단하고 암 진행을 늦춰 환자의 생존율을 향상시키는 새로운 클래스에 속하는 전립선암 치료제를 말합니다. 이러한 첨단 치료법의 채용 확대는 임상적 성공률 증가, 양호한 치료 성과, 건강 관리 의식 증가에 의해 추진되고 있습니다. 차세대 안드로겐 수용체 억제제의 대표인 얼리다는 강화된 효능과 안전성을 제공하며 종양 전문의들 사이에서 우선적으로 선택되는 약제가 되고 있습니다. 예를 들면, 'Journal of Clinical Oncology'잡지에 게재된 임상 데이터에 의하면, 비전이성 거세 저항성 전립선암 환자에 있어서, 아팔루타마이드(얼리다)를 사용한 치료는 위약에 비해 전이 또는 사망 위험을 72% 낮추는 것으로 나타났습니다. 따라서 첨단 안드로겐 수용체 억제제의 채용 확대가 얼리다 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 얼리다 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 얼리다 시장 : 성장률 분석
세계의 얼리다 시장 실적 : 규모와 성장(2019-2024년)
세계의 얼리다 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 얼리다 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 얼리다 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
브랜드
제네릭
세계의 얼리다 시장 : 적응증 또는 질환 단계별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
전이성 거세 저항성 전립선암(mCRPC)
비전이성 거세 저항성 전립선암(nmCRPC)
전이성 거세 감수성 전립선암(mCSPC)
세계의 얼리다 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원 약국
소매 약국
기타 유통 채널
세계의 얼리다 시장 : 환자 유형 및 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원
전문 클리닉 또는 종양 센터
가정 치료 및 외래 진료 환경
세계의 얼리다 시장 세분화 : 브랜드, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
혁신 브랜드
공동 브랜드
라이선스 취득이 끝난 브랜드 확장
세계의 얼리다 시장 세분화 : 제네릭, 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
무브랜드 제네릭
인가 제네릭
병행 수입 제네릭
제7장 지역별 및 국가별 분석
세계의 얼리다 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 얼리다 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
얼리다 시장 : 경쟁 구도
얼리다 시장 : 기업 프로파일
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
제332장 세계 시장의 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
얼리다 시장(2029년) : 새로운 기회를 제공하는 국가
얼리다 시장(2029년) : 새로운 기회를 제공하는 부문
얼리다 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Erleada is a prescription medication used to treat specific forms of prostate cancer, including non-metastatic and metastatic castration-resistant prostate cancer. It functions by blocking androgen receptors, helping slow the growth and spread of cancer cells that depend on male hormones. It is administered orally and is often combined with hormone therapy to improve treatment effectiveness.
The main types in the Erleada market include branded and generic products. Branded Erleada refers to the original, patented formulation of apalutamide developed and marketed by Janssen Pharmaceuticals, created to inhibit androgen receptor signaling in prostate cancer cells. It is primarily used to treat prostate cancer by delaying disease progression and improving overall survival outcomes for men with advanced or treatment-resistant forms of the condition. Key indications or disease stages include metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-sensitive prostate cancer (mCSPC). Distribution channels include hospital pharmacies, retail pharmacies, and others. The major patient groups or end users include hospitals, specialty clinics or oncology centers, and home care or outpatient settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The erleada market research report is one of a series of new reports from The Business Research Company that provides erleada market statistics, including the erleada industry global market size, regional shares, competitors with the erleada market share, detailed erleada market segments, market trends, and opportunities, and any further data you may need to thrive in the erleada industry. This erleada market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The erleada market size has grown strongly in recent years. It will grow from $2.76 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to the increasing incidence of hormone-resistant prostate cancer, rising use of androgen deprivation therapies, growing investment in oncology research, expanding access to advanced cancer care, and increasing physician preference for oral prostate cancer medications.
The erleada market size is expected to see strong growth in the next few years. It will grow to $4.31 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising demand for minimally invasive cancer treatments, increasing adoption of next-generation anti-androgens, growing healthcare expenditure in oncology, expanding availability of precision medicine programs, and greater awareness of the survival benefits associated with early treatment. Major trends expected in the forecast period include technological advancements in clinical trial design, innovations in androgen receptor-targeting mechanisms, the development of digital health tools for cancer management, ongoing research and development in radioligand and combination therapies, and advancements in artificial intelligence-based cancer diagnostics.
The rising prostate cancer prevalence is expected to propel the growth of the Erleada market going forward. Prostate cancer refers to a malignant tumor that develops in the prostate gland, a part of the male reproductive system. The rising prevalence of prostate cancer is driven by increasing life expectancy, as older age significantly raises the likelihood of developing this disease. Erleada helps treat prostate cancer by blocking androgen receptors, preventing male hormones from stimulating the growth and spread of cancer cells. For instance, according to data published by the Australian Government in November 2025, around 28,868 new prostate cancer cases were reported, accounting for about 30% of all new male cancer diagnoses, with an estimated 3,975 deaths. Therefore, the rising prostate cancer prevalence is driving the growth of the Erleada market.
The increasing adoption of advanced androgen receptor inhibitors is expected to propel the growth of the Erleada market going forward. Advanced androgen receptor inhibitors refer to a new class of prostate cancer drugs that more effectively block androgen receptor signaling, slowing cancer progression and improving patient survival rates. The increasing adoption of these advanced therapies is driven by rising clinical success rates, favorable treatment outcomes, and growing healthcare awareness. Erleada, as one of the leading next-generation androgen receptor inhibitors, offers enhanced efficacy and safety, making it a preferred choice among oncologists. For instance, according to clinical data published in the Journal of Clinical Oncology, treatment with apalutamide (Erleada) demonstrated a 72% reduction in the risk of metastasis or death compared to placebo in patients with non-metastatic castration-resistant prostate cancer. Therefore, the increasing adoption of advanced androgen receptor inhibitors is driving the growth of the Erleada market.
Major companies operating in the Erleada market are focusing on innovation, such as reduced pill burden, to enhance patient convenience, improve treatment adherence, and provide more personalized therapy options for prostate cancer patients. Reduced pill burden refers to lowering the number of pills a patient needs to take by combining medications or reducing dosing frequency. It helps improve treatment adherence and overall patient convenience. For instance, in April 2023, Johnson & Johnson, a U.S.-based company that develops, manufactures, and sells pharmaceuticals for various diseases such as oncology, immunology, and neuroscience, as well as medical devices for surgery, orthopedics, and vision, announced the availability of an additional tablet strength of Erleada (apalutamide) in the United States. The introduction of the 240 mg tablet provides the first and only option for a once-daily, single-tablet androgen receptor inhibitor approved for the treatment of patients with non-metastatic castration-resistant prostate cancer and for the treatment of patients with metastatic castration-sensitive prostate cancer.
Major companies operating in the erleada market are Johnson & Johnson
North America was the largest region in the erleada market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in erleada report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the erleada market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The erleada market consists of sales of erleada 60 mg tablets, and erleada 240 mg tablets. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Erleada Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on erleada market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for erleada ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The erleada market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Branded; Generic
2) By Indication Or Disease Stage: Metastatic Castration-Resistant Prostate Cancer (mCRPC); Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC); Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
4) By Patient Type Or End User: Hospitals; Specialty Clinics Or Oncology Centers; Home Care Or Outpatient Settings
Subsegments:
1) By Branded: Innovator Brand; Co-Branded Formulation; Licensed Brand Extension
2) By Generic: Unbranded Generic; Authorized Generic; Parallel Import Generic
Companies Mentioned: Johnson & Johnson
Countries:
Table of Contents
1. Executive Summary
2. Erleada Market Characteristics
3. Erleada Market Trends And Strategies
4. Erleada Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Erleada Growth Analysis And Strategic Analysis Framework
5.1. Global Erleada PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Erleada Market Growth Rate Analysis
5.4. Global Erleada Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Erleada Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Erleada Total Addressable Market (TAM)
6. Erleada Market Segmentation
6.1. Global Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded
Generic
6.2. Global Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
6.3. Global Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
6.4. Global Erleada Market, Segmentation By Patient Type Or End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics Or Oncology Centers
Home Care Or Outpatient Settings
6.5. Global Erleada Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Innovator Brand
Co-Branded Formulation
Licensed Brand Extension
6.6. Global Erleada Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Unbranded Generic
Authorized Generic
Parallel Import Generic
7. Erleada Market Regional And Country Analysis
7.1. Global Erleada Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Erleada Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Erleada Market
8.1. Asia-Pacific Erleada Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Erleada Market
9.1. China Erleada Market Overview
9.2. China Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Erleada Market
10.1. India Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Erleada Market
11.1. Japan Erleada Market Overview
11.2. Japan Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Erleada Market
12.1. Australia Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Erleada Market
13.1. Indonesia Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Erleada Market
14.1. South Korea Erleada Market Overview
14.2. South Korea Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Erleada Market
15.1. Western Europe Erleada Market Overview
15.2. Western Europe Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Erleada Market
16.1. UK Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Erleada Market
17.1. Germany Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Erleada Market
18.1. France Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Erleada Market
19.1. Italy Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Erleada Market
20.1. Spain Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Erleada Market
21.1. Eastern Europe Erleada Market Overview
21.2. Eastern Europe Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Erleada Market
22.1. Russia Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Erleada Market
23.1. North America Erleada Market Overview
23.2. North America Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Erleada Market
24.1. USA Erleada Market Overview
24.2. USA Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Erleada Market
25.1. Canada Erleada Market Overview
25.2. Canada Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Erleada Market
26.1. South America Erleada Market Overview
26.2. South America Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Erleada Market
27.1. Brazil Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Erleada Market
28.1. Middle East Erleada Market Overview
28.2. Middle East Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Erleada Market
29.1. Africa Erleada Market Overview
29.2. Africa Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Erleada Market Competitive Landscape And Company Profiles
30.1. Erleada Market Competitive Landscape
30.2. Erleada Market Company Profiles
30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
332. Global Erleada Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Erleada Market
34. Recent Developments In The Erleada Market
35. Erleada Market High Potential Countries, Segments and Strategies
35.1 Erleada Market In 2029 - Countries Offering Most New Opportunities
35.2 Erleada Market In 2029 - Segments Offering Most New Opportunities
